[go: up one dir, main page]

ITUA20162242A1 - Un nuovo anticorpo anti-erbb2 - Google Patents

Un nuovo anticorpo anti-erbb2

Info

Publication number
ITUA20162242A1
ITUA20162242A1 ITUA2016A002242A ITUA20162242A ITUA20162242A1 IT UA20162242 A1 ITUA20162242 A1 IT UA20162242A1 IT UA2016A002242 A ITUA2016A002242 A IT UA2016A002242A IT UA20162242 A ITUA20162242 A IT UA20162242A IT UA20162242 A1 ITUA20162242 A1 IT UA20162242A1
Authority
IT
Italy
Prior art keywords
new anti
erbb2 antibody
erbb2
antibody
new
Prior art date
Application number
ITUA2016A002242A
Other languages
English (en)
Inventor
Leonardo Sibilio
Patrizio Giacomini
Original Assignee
St Biochimico Italiano Giovanni Lorenzini Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Biochimico Italiano Giovanni Lorenzini Spa filed Critical St Biochimico Italiano Giovanni Lorenzini Spa
Priority to ITUA2016A002242A priority Critical patent/ITUA20162242A1/it
Priority to CN201780022198.5A priority patent/CN109071671B/zh
Priority to KR1020187031322A priority patent/KR20180133437A/ko
Priority to US16/090,505 priority patent/US11220553B2/en
Priority to PCT/EP2017/057697 priority patent/WO2017167967A1/en
Priority to EP17719810.8A priority patent/EP3436483B1/en
Priority to JP2018551292A priority patent/JP7055750B2/ja
Publication of ITUA20162242A1 publication Critical patent/ITUA20162242A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ITUA2016A002242A 2016-04-01 2016-04-01 Un nuovo anticorpo anti-erbb2 ITUA20162242A1 (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITUA2016A002242A ITUA20162242A1 (it) 2016-04-01 2016-04-01 Un nuovo anticorpo anti-erbb2
CN201780022198.5A CN109071671B (zh) 2016-04-01 2017-03-31 Erbb2靶向抗体
KR1020187031322A KR20180133437A (ko) 2016-04-01 2017-03-31 신규의 erbb2-표적화 항체
US16/090,505 US11220553B2 (en) 2016-04-01 2017-03-31 ERBB2-targeting antibody
PCT/EP2017/057697 WO2017167967A1 (en) 2016-04-01 2017-03-31 Erbb2-targeting antibody
EP17719810.8A EP3436483B1 (en) 2016-04-01 2017-03-31 Erbb2-targeting antibody
JP2018551292A JP7055750B2 (ja) 2016-04-01 2017-03-31 Ｅｒｂｂ２ターゲティング抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A002242A ITUA20162242A1 (it) 2016-04-01 2016-04-01 Un nuovo anticorpo anti-erbb2

Publications (1)

Publication Number Publication Date
ITUA20162242A1 true ITUA20162242A1 (it) 2017-10-01

Family

ID=56235949

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A002242A ITUA20162242A1 (it) 2016-04-01 2016-04-01 Un nuovo anticorpo anti-erbb2

Country Status (7)

Country Link
US (1) US11220553B2 (it)
EP (1) EP3436483B1 (it)
JP (1) JP7055750B2 (it)
KR (1) KR20180133437A (it)
CN (1) CN109071671B (it)
IT (1) ITUA20162242A1 (it)
WO (1) WO2017167967A1 (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3455260B1 (en) * 2016-05-12 2022-07-06 Agency for Science, Technology and Research Anti-erbb-2 antibodies and uses thereof
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011147982A2 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
WO2013164689A2 (en) * 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
WO2015195917A1 (en) * 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Monoclonal antibodies against her2 epitope and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
KR20150101915A (ko) * 2014-02-27 2015-09-04 삼성전자주식회사 3차원 gui 화면의 표시 방법 및 이를 수행하기 위한 디바이스

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011147982A2 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
WO2013164689A2 (en) * 2012-05-02 2013-11-07 Lantto, Johan Humanized pan-her antibody compositions
WO2015130173A1 (en) * 2014-02-28 2015-09-03 Merus B.V. Antibody that binds erbb-2 and erbb-3
WO2015195917A1 (en) * 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Monoclonal antibodies against her2 epitope and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE MARCO ARIO: "Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies", CRC CRITICAL REVIEWS IN BIOTECHNOLOGY, CRC PRESS, BOCA RATON, FL, US, vol. 33, no. 1, 1 March 2013 (2013-03-01), pages 40 - 48, XP009174043, ISSN: 0738-8551, DOI: 10.3109/07388551.2012.665353 *
ROCKBERG J ET AL: "Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies", MOLECULAR ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 3, 1 June 2009 (2009-06-01), pages 238 - 247, XP026110113, ISSN: 1574-7891, [retrieved on 20090131], DOI: 10.1016/J.MOLONC.2009.01.003 *
Y MENG ET AL: "A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors", ONCOGENESIS, vol. 5, no. 3, 21 March 2016 (2016-03-21), pages e211, XP055323232, DOI: 10.1038/oncsis.2016.25 *

Also Published As

Publication number Publication date
WO2017167967A1 (en) 2017-10-05
CN109071671B (zh) 2022-11-04
US11220553B2 (en) 2022-01-11
US20190112387A1 (en) 2019-04-18
EP3436483B1 (en) 2021-09-15
KR20180133437A (ko) 2018-12-14
EP3436483A1 (en) 2019-02-06
JP2019512258A (ja) 2019-05-16
CN109071671A (zh) 2018-12-21
JP7055750B2 (ja) 2022-04-18

Similar Documents

Publication Publication Date Title
IL272227A (en) Anti-tigit antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3692442A4 (en) PARTIAL RESTORATION OF A DATABASE
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
EP3684806A4 (en) NEW ANTI-CD3EPSILON ANTIBODIES
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
MA47676A (fr) Polythérapie
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
MA46285A (fr) Polythérapie
CL2018000959S1 (es) Un respirador
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
MA49921A (fr) Polythérapie
ES1123386Y (es) Un quitasol
EP3400163A4 (en) RAIL FOR A VEHICLE
EP3579879A4 (en) ANTI-BODY ANTI-KIR3DL1
DK3484921T3 (da) Anti-IL-22R antistoffer
ITUA20161830A1 (it) Sedia a rotelle.
LT3456736T (lt) Antikūnų variantai
ITUA20162242A1 (it) Un nuovo anticorpo anti-erbb2
IT201700062839A1 (it) Un veicolo
EP3720492A4 (en) ANTI-RSPO3 ANTIBODIES
EP3604518A4 (en) ANTI-GPR20 ANTIBODY
FR3024520B1 (fr) Vanne thermostatique a manchon